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Abstract
Heat shock protein (Hsp)70 is one of the most important stress-inducible proteins. Intracellular Hsp70 not only mediates
chaperone-cytoprotective functions but can also block multiple steps in the apoptosis pathway. In addition, Hsp70 is
actively released into the extracellular milieu, thereby promoting innate and adaptive immune responses. Thus, Hsp70 may
be a critical molecule in multiple sclerosis (MS) pathogenesis and a potential target in this disease due to its immunological
and cytoprotective functions. To investigate the role of Hsp70 in MS pathogenesis, we examined its immune and
cytoprotective roles using both in vitro and in vivo experimental procedures. We found that Hsp70.1-deficient mice were
more resistant to developing experimental autoimmune encephalomyelitis (EAE) compared with their wild-type (WT)
littermates, suggesting that Hsp70.1 plays a critical role in promoting an effective myelin oligodendrocyte glycoprotein
(MOG)-specific T cell response. Conversely, Hsp70.1-deficient mice that developed EAE showed an increased level of
autoreactive T cells to achieve the same production of cytokines compared with the WT mice. Although a neuroprotective
role of HSP70 has been suggested, Hsp70.1-deficient mice that developed EAE did not exhibit increased demyelination
compared with the control mice. Accordingly, Hsp70 deficiency did not influence the vulnerability to apoptosis of
oligodendrocyte precursor cells (OPCs) in culture. Thus, the immunological role of Hsp70 may be relevant in EAE, and
specific therapies down-regulating Hsp70 expression may be a promising approach to reduce the early autoimmune
response in MS patients.
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Introduction
Heat shock proteins (HSPs) are widely known as conserved
cytoprotective proteins due to their function as chaperones, in
which they help to properly fold newly synthesised proteins,
prevent protein aggregation and degrade unstable and misfolded
proteins [1–5]. Under stressful conditions, the expression of
specific HSPs is induced to control cellular damage and restore
cellular homeostasis [6–8]. In the HSP70 family, Hsp70 (encoded
by the Hsp72, Hsp70.1 and Hsp70.3 genes) is one of the most
important stress-inducible proteins [9]. Intracellular Hsp70 not
only mediates chaperone-cytoprotective functions but also can
block multiple steps in the apoptosis pathway [10–12]. In addition,
Hsp70 is actively released into the extracellular milieu where it can
act as cytokine and peptide adjuvant, thereby promoting both the
innate and adaptive immune responses [13–16].
Multiple sclerosis (MS) is an autoimmune disorder in which
activated CD4+ T cells initiate an inflammatory response in the
central nervous system (CNS). This activation results in inflam-
mation, gliosis, demyelination as well as oligodendrocyte and
neuronal loss [17]. Accordingly, immunomodulation and cyto-
protection of specific cell populations in the CNS have been
established as two key aspects of MS therapeutics. Nevertheless,
MS treatments have mainly focused on controlling the immune
response due to the lack of effective neuroprotective treatments.
Previous studies have indicated that Hsp70 is a critical molecule
in MS pathogenesis [18] and a potential disease target due to its
immunological and cytoprotective functions.
The inflammatory and oxidative environment taking place in
the CNS of MS patients and in the experimental autoimmune
encephalomyelitis (EAE) animal model induces the overexpression
of most of HSP, including Hsp70 [19–23]. This inflammatory-
Hsp70 induction occurs predominantly in oligodendrocytes [24]
and, as in other experimental models of neuropathological diseases
such as Alzheimer’s and Parkinson’s diseases [25,26], Hsp70
overexpression in the CNS of MS patients and EAE animals
suggests a neuroprotective role for this protein. By contrast,
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because Hsp70 can act as an adjuvant Hsp70–myelin basic protein
(MBP) and Hsp70–proteolipid protein (PLP) complexes have been
found in MS lesions, which have been considered highly
immunogenic [19,27,28].
Recently, our group has shown a baseline increase in HSPA1A
gene expression in peripheral blood mononuclear cells (PBMCs)
obtained from MS patients compared with those of healthy donors
(HDs). Gene expression analyses were confirmed by Hsp70.1
protein expression in both T lymphocytes (CD4+ and CD8+) and
monocytes from MS patients under basal conditions, which could
reflect immunological activation in MS patients. Our data
suggested altered immune responses in MS and may indicate a
state of chronic stress or increased vulnerability to physiological
immune responses in MS patients [29].
In this study, we aimed to investigate the role of Hsp70 in MS
pathogenesis using both in vitro and in vivo experimental
procedures. In vitro studies showed that subjecting mixed CNS
cultures to inflammatory stress resulted into oligodendrocyte
precursor cells (OPCs) apoptosis. However, this OPC vulnerability
was not influenced by Hsp70 deficiency. In the EAE model we
demonstrated that Hsp70 is one of the molecules that promote an
efficient antigen-specific immune response required to develop
EAE, but it is not crucial to protect CNS cells from the
inflammatory damage. Thus, Hsp70.1 inhibition/down-regulation
may be an effective therapeutic strategy to reduce the early
autoimmune response in MS patients.
Materials and Methods
Mice
C57BL/6J Hsp70.1 knock-out (KO) mice [30] and age- and
sex-matched WT littermates were purchased from Macrogen
(Seoul, Korea) and used to establish mouse colonies that were bred
in our animal facility at Vall d9Hebron Research Institute. Seven-
week-old female C57BL/6J mice were purchased from Harlan
Laboratories (Italy) for the Hsp70.1 knock-down studies. The mice
were housed under standard light- and climate-controlled condi-
tions, and standard chow and water were provided ad libitum. All
experiments were performed in strict accordance with EU and
governmental regulations (Generalitat de Catalunya Decret 214/
97 30th July). The Ethics Committee on Animal Experimentation
of the Vall d9Hebron Research Institute approved all procedures
described in this study (protocol number: 11/06 CEEA). Measures
to improve welfare assistance and clinical status as well as endpoint
criteria were established to minimise suffering and ensure animal
welfare. Briefly, wet food pellets are placed on the bed-cage when
the animals begin to develop clinical signs to facilitate access to
food and hydration. If weight loss was greater than 15%, mice
received subcutaneously 0.5 ml of 10% glucose. Mice suffering
severe disease (score 5) or 30% weight loss were euthanized in
accordance with our governmental ethical guidelines.
EAE induction and follow-up analyses
Anaesthetised mice were immunised with subcutaneous injec-
tions of 200 ml of phosphate buffered saline (PBS) containing
200 mg of 35–55 myelin oligodendrocyte glycoprotein peptide
(MOG35–55) (Proteomics Section, Universitat Pompeu Fabra,
Barcelona, Spain) emulsified in complete Freund’s Adjuvant
(CFA) (Sigma Chemical, St. Louis, MO, USA) containing 4 mg/
ml Mycobacterium tuberculosis H37RA (Difco Laboratories,
Detroit, MI, USA). At day 0 and 2 post-immunisation (p.i.), the
mice received 250 ng of pertussis toxin intravenously (Sigma
Chemical). A total of 51 Hsp70.1 KO and 36 WT mice were
immunised in three independent experiments. A group of 3–4
animals per group were used as control mice, which were
immunised in the same manner using PBS in the absence of the
peptide. All animals were weighed and examined daily for welfare
and clinical status as well as neurological signs according to the
following criteria: 0, no clinical signs; 0.5, partial loss of tail tonus
for at least two consecutive days; 1, paralysis of the whole tail; 2,
paresis of one or both hind limbs; 3, hind limb paraplegia; 4,
tetraparesis; 5, tetraplegia; and 6, death [31]. Clinical follow-up
analyses were performed in a blinded manner by two observers.
All data presented are in accordance with the guidelines suggested
for EAE publication [32].
In vivo siRNA administration
The C57BL/6J WT mice were immunised as previously
described. At day 7 p.i., once the first EAE clinical symptoms
were detected, the animals were randomised into two groups (n = 5
mice in each group) and then were intravenously injected with
either 200 ml of PBS containing 2 mg/kg of a pool of four specific
mouse Hsp70.1 (HSPA1B, ref. E-065710) siRNAs or non-
targeting siRNAs (control, ref. D-001910) (accell SMART pool
siRNA, Dharmacon, Thermo Fisher Scientific, Waltham, MA,
USA). At day 14 p.i., when the disease had already been
established, the mice received a second dose of Hsp70.1 or non-
targeting siRNA. The administration of the siRNAs was
performed in a blinded manner.
Splenocyte proliferation and cytokine production
At day 12 p.i. and at the end of the experiment (day 29 p.i.), a
subgroup of Hsp70.1 KO and WT mice (day 12pi: n = 4 in each
group and day 29pi: WT n = 3, Hsp70.1 KO n = 5) were
euthanized using carbon dioxide (.70%), and the spleens were
removed. Spleen cell suspensions were prepared by grinding the
spleens through a wire mesh, and the resulting cells were cultured
in 96-well plates at 26105 cells/well in a total volume of 200 ml of
Iscove’s modified Dulbecco’s medium (IMDM) (PAA Laboratories
GmbH, Pasching, Austria) supplemented with 10% HyCloneH
FetalClone I (Thermo Fisher Scientific, Waltham, MA, USA),
50 mM 2-mercaptoethanol (Sigma Chemical), 2 mM glutamine,
50 U/ml penicillin and 50 mg/ml streptomycin, all of which were
obtained from Gibco BRL (Paisley, UK). The cultures (five
replicas for each condition) were stimulated with 5 mg/ml
MOG35–55. The supernatants (50 ml/well) were harvested after
48 h of culture and stored to further assess the cytokine release.
Next, 1 mCi/well of [3H]-thymidine (PerkinElmer, Waltham, MA,
USA) was added to each well. The cultures were maintained under
the same conditions for an additional 18 h, and the levels of
incorporated radioactivity were determined using a scintillation
counter (Wallac, Turku, Finland). The stimulation index (SI)
values for each sample were calculated as the mean counts per
minute (cpm) of the five replicas of MOG35–55-stimulated cultures
divided by the mean cpm of the five replicas from the non-
stimulated cultures. The cytokine secretion was determined in the
culture supernatants using the FlowCytomix Th1/Th2/Th17 10
plex kit (Bender MedSystems Inc., Burlingame, CA) and
FacsCanto cytometer (Becton Dickinson) according to the
manufacturer’s instructions.
Primary antibodies
For the histopathological studies, the following primary
antibodies and dilutions were used: anti-CD45 (pan-leukocyte
marker) (rat IgG2b, 1:300, R&D Systems, Abingdon, OX, UK),
anti-CD3 (T lymphocytes) (rabbit polyclonal, 1:100, Dako,
Glostrup, Denmark), anti-GFAP (astrocytes) (rabbit polyclonal,
1:500, Dako), Lycopersicon esculentum agglutinin (LEA, microg-
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lia/macrophages) (1:100, Sigma), anti-neurofilament H non-
phosphorylated (SMI32, axonal damage) (mouse IgG, 1:100,
Covance Inc.), anti-NG2 (oligodendrocyte progenitor cells) (rabbit
polyclonal, 1:200, Merck Millipore, Billerica, MA, USA), anti-
malondialdehyde (MDA, lipid-oxidation) (rabbit polyclonal, 1:100,
Alpha Diagnostic Int., San Antonio, TX, USA), anti-nitrotyrosine
(NITT, protein-oxidation) (rabbit polyclonal, 1:100, Alpha Diag-
nostic Int.), anti-heme oxygenase 1 (HOx, oxidative stress) (rabbit
polyclonal, 1:100, Enzo Life Sciences, Lausen CH, Switzerland)
and anti-inducible nitric oxide synthase (iNOS2, oxidative stress)
(rabbit polyclonal, 1:100, Santa Cruz Biotechnologies, Dallas, TX,
USA).
For immunostaining of the CNS cultures, the following primary
antibodies were used: anti-O4 (OPC) (mouse IgM, 1:5, hybridoma
generously donated by Dr. Sommer), anti-myelin basic protein
(MBP, mature oligodendrocytes) (chicken IgY, 1:200, Millipore),
anti-cleaved Caspase 3 (Casp3) (rabbit polyclonal, 1:500, Cell
Signaling Technologies, Danvers, MA, USA), anti-NeuN (neu-
rons) (mouse IgG1, 1:300, Merck Millipore), anti-GFAP (astro-
cytes) (rabbit polyclonal, 1:500, Dako), isolectin B4 conjugated to
fluorescein-isothiocyanate (FITC) (mouse microglial cells) (1:1000,
Sigma), anti-CD11b/c (rat microglial cells) (mouse IgG2a, 1:100,
BD Pharmingen, San Diego, CA) and anti-CD68 (activated rat
microglial cells) (mouse IgG1 1:200, AbD Serotec, UK).
Histopathology
For the histopathological studies, Hsp70.1 KO and WT mice
were euthanised at day 12 p.i. (WT: n = 3 and Hsp70.1 KO: n = 6)
or at the end of the experiment, day 29 p.i. (WT: n = 7 and
Hsp70.1 KO: n = 13). The mice treated with Hsp70.1 (n = 5) or
non-targeting siRNAs (n = 5) were euthanised at the end of the
experiment. The brains and spinal cords were removed, fixed with
4% paraformaldehyde and embedded in paraffin wax. Four-
micrometre-thick tissue sections were stained with hematoxylin
and eosin (HE) and Klu¨ver-Barrera (KB) to assess the degree of
inflammation and demyelination, respectively. Immunostaining
was also performed. Briefly, endogenous peroxidase activity was
blocked by incubating the tissue sections in 2% hydrogen
peroxide, 70% methanol and PBS for 20 min. Antigen unmasking
was performed in 10 mM citrate (pH = 6) for anti-CD45, SMI32,
NG2, NITT, HOx and iNOs or protease type XIV (Sigma
Chemical) for anti-CD3 antibody. Non-specific protein binding
was blocked using 2% bovine albumin in PBS (blocking solution)
at room temperature for 1 h. The sections were incubated
overnight at 4uC using the primary antibodies detailed in the
Primary antibodies section. Next, all of the samples were
incubated at room temperature for 1 h with biotinylated anti-
rabbit, anti-rat or anti-mouse IgG (all from DakoCytomation)
(1:200 dilution in blocking solution) secondary antibodies. Finally,
the avidin–biotin-peroxidase complex (ImmunoPure ABC Perox-
idase Staining Kits, Pierce, IL, USA), which was diluted 1:100 in
PBS, was added for 1 h at room temperature. The peroxidase
reaction was visualised with 2.5 mg/ml 3,39-diaminobenzidine
and 0.05% hydrogen peroxide. The primary antibodies were
omitted in the negative controls. No signal was observed in any of
the control slides.
Cell infiltration was evaluated using HE staining according to
the following criteria: 0, no lesion; 1, cellular infiltration only in the
meninges; 2, very discrete and superficial infiltrates in the
parenchyma; 3, moderate infiltration (less than 25%) in the white
matter; 4, severe infiltration (less than 50%) in the white matter;
and 5, more severe infiltration (greater than 50%) in the white
matter. Demyelination (KB staining) was scored as follows: 0, no
demyelination; 1, little demyelination, only around the infiltrates
and involving less than 25% of the white matter; 2, demyelination
involving less than 50% of the white matter; and 3, diffuse and
widespread demyelination involving more than 50% of the white
matter. Quantification of the stained cells was performed in three
matched areas (0.25 mm2) along the spinal cord. The HE and KB
staining and all immunostaining markers were evaluated in a
blinded manner.
CNS cell cultures
Brains were obtained from 1- to 2-day-old postnatal Hsp70.1
KO or WT mice and dissected in Hanks buffer (Hanks 10x,
Gibco), supplemented with 0.01 M HEPES buffer, 0.75% sodium
bicarbonate (Gibco) and 1% penicillin/streptomycin. A pool of 3-5
WT or Hsp70.1 KO dissected brains was enzymatically dissoci-
ated with papain (30 mg/ml in DMEM with 0.24 mg/ml L-
cysteine and 40 mg/ml DNase I) and then mechanically dissoci-
ated using 150 mm and 65 mm filters. To obtain CNS preparation
enriched in oligodendrocyte lineage cells, a percoll density
gradient was performed as previously described [33] to obtain
the fraction of cells enriched in oligodendroglial precursor cells.
The cells were resuspended in modified Bottenstein Sato medium
(DMEM containing 0.5% foetal calf serum (FCS), 2 mM L-
glutamine, 10 mM insulin, 5 ng/ml sodium selenite, 100 mg/ml
transferrin, 0.28 mg/ml albumin, 60 ng/ml progesterone, 16 mg/
ml putrescine, 40 ng/ml triiodothyronine and 30 ng/ml L-
thyroxine), and 40,000 cells per well were seeded onto poly-L-
lysine-coated (40 mg/ml, Sigma) glass coverslips in 24-well plates.
Preparation of microglial cells
Rat microglial cells were obtained from Wistar neonatal glial
mix cultures. Brains were dissected and dissociated using the
papain and mechanical procedure (as indicated above). After
filtration, cells were cultured in DMEM containing 10% FCS in
T125 flasks coated with polyethylenimine. At 10 days in vitro, the
flasks were subjected to 1 h of shaking at 180 rpm. This procedure
detaches preferentially microglial cells that were then washed,
counted, and used for induction of inflammatory stress in mixed
CNS cultures.
Induction of inflammation in mixed CNS cell cultures
The CNS cell cultures were challenged with an inflammatory
stress stimulus for 24 h. The inflammatory stimulus consisted on
the replacement of 50% of the cultured medium by culture
medium containing 20,000 or 16,000 microglial cells and different
concentrations of LPS and IFN-c (10 mg/ml LPS plus 150 ng/ml
IFN-c, 1 mg/ml LPS plus 100 ng/ml IFN-c or 100 ng/ml LPS
plus 100 ng/ml IFN-c). CD11b/c and CD68 staining was
performed to confirm microglial activation. Cells co-cultured with
the same amount of microglial cells without LPS and IFN-c
stimulus were used as control CNS cultures.
Immunocytochemistry and detection of apoptosis
Following 24 h of inflammatory or non-stimulated culture
conditions, the CNS cells were stained with anti-O4 (marker for
late OPCs), anti-MBP (marker for mature oligodendrocytes), anti-
NeuN (marker for neurons), and anti-Casp3 (marker for apoptotic
cells) antibodies (see the Primary antibodies section). The cells
were washed and fixed with 4% paraformaldehyde for 15 min at
room temperature. After washing, the cells were incubated in
blocking solution (0.1% Triton X100, 10% horse serum) for
20 min at room temperature. The samples were incubated with
the primary antibodies overnight at 4uC or for 1 h at room
temperature in blocking solution. After several washes, Alexa-488-
Hsp70 in EAE Pathogenesis
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or Alexa-568-conjugated-secondary antibodies were incubated for
90 min at room temperature. Secondary antibodies obtained from
Molecular Probes (Invitrogen, Cergy, Pontoise, France) were used
at a 1:1000 dilution. The cell nuclei were stained with Hoechst
solution (1 mg/ml), and the immunocytochemistry preparations
were mounted in Fluoromount-G (Clinisciences, France). For the
O4 staining, in vivo immunocytochemistry was performed by
incubation with the anti-O4 antibody for 30 min at 37uC in
DMEM containing 10% horse serum followed by fixation of the
cells with 4% paraformaldehyde. Negative controls were per-
formed by omitting the primary antibodies. The stainings were
observed by using a fluorescence microscope Zeiss Imager.Z1.
Images were acquired with an AxioCam camera equipped with an
ApoTome module and analysed using ImageJ software. The
percentage of Casp3+ cells from each culture was calculated as the
sum of the number of positive cells obtained from three
representative microscope fields divided by the sum of the total
number of cells (cells positive for Hoechst staining). The
percentage of O4+Casp3+, MBP+Casp3+, and NeuN+Casp3+
cells was calculated as the sum of double positive cells divided by
the sum of the total number of each population (O4+, MBP+, and
NeuN+ cells). To determine the effect of the inflammatory
stimulus, the fold change values of each population was calculated
in WT and Hsp70.1 KO mice with respect to their matched non-
stimulated control cultures.
Statistical analysis
The data were expressed as the mean6 standard deviation (SD)
values unless otherwise stated. Statistical analyses were performed
using SPSS 17.0 (SPSS Inc, Chicago, IL, USA) for MS-Windows
and Graphpad Prism 5. The Mann-Whitney test was applied to
compare the mean values between groups; however, for large
samples (n$30) and very small samples (n#3), an unpaired t-test
was performed [34]. A paired t-test was used to analyse the effect
of the inflammatory stress on the cell cultures. Fisher’s exact test
Figure 1. Role of Hsp70 in EAE development and clinical course. A. Hsp70.1 knock-out (Hsp70 KO) mice showed a reduced susceptibility to
EAE compared with the wild-type (WT) mice after immunisation with the MOG35–55 peptide (86.3% vs. 100%, p= 0.038; n = 51 and n=36,
respectively) resulting in less disease severity in the Hsp70.1 KO mice compared with the WT mice during the chronic phase of EAE (p = 0.029). B.
When Hsp70.1 expression was down-regulated using the systemic administration of siRNA on days 7 and 14 after immunisation, the mice developed
a milder clinical course compared with the mice administered non-targeting siRNA (n = 5 in each group). The arrows indicate when the siRNA was
administered. The data were expressed as the mean of the clinical score. The error bars correspond to the standard error of the mean (SEM). C.
Summary of the EAE clinical data in WT and Hsp70.1 KO mice and in WT mice treated with Hsp70.1 or non-targeting siRNA. The data were expressed
as the mean6SD. *p,0.05.
doi:10.1371/journal.pone.0105737.g001
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was used to compare qualitative variables. Differences were
considered statistically significant when p,0.05.
Results
Reduced EAE susceptibility in Hsp70.1-deficient mice
To study the role of the inducible Hsp70 protein in EAE
pathogenesis, we immunised a total of 51 Hsp70.1 KO mice and
36 WT littermates with MOG35–55, in three independent
experiments. Mice developed a chronic non-remitting EAE
clinical course. We observed a reduction in the incidence of
EAE in the Hsp70.1 KO mice compared with their WT
littermates (86.3% vs. 100%, p = 0.038). Because WT mice were
100% incident and remaining without clinical symptoms is the
best improvement of the disease, EAE incident and non-incident
mice were included in the statistical analysis. The severity of the
disease in the Hsp70.1 KO mice was reduced during the chronic
phase of EAE (from day 15 p.i. to day 29 p.i.), being the chronic
cumulative clinical score reduced in the Hsp70.1 KO mice
compared with the WT mice (51.79629.40 vs. 63.22612.70,
p = 0.029) (Fig. 1A and C).
To guarantee that Hsp70.1 KO mice do not have any
compensatory mechanisms to supply Hsp70 lacking that could
mask its real role in EAE, C57BL/6J WT mice were immunised
with MOG35–55. At day 7 p.i., once the first EAE clinical
symptoms were detected, the animals were randomised into two
groups and then intravenously injected with Hsp70.1-specific
siRNA or non-targeting siRNA (n = 5 in each group, 3 mice with
clinical score = 0 and 2 mice with clinical score = 0.5 in both
groups). At day 14 p.i., when the disease had already been
established, the mice received a second dose of Hsp70.1 or non-
targeting siRNA. Consistent with previous results, Hsp70.1 knock-
down mice showed milder EAE progression compared to control
mice administrated with non-targeting siRNA, as before EAE
incident and non-incident mice were included in the statistical
analysis (Fig. 1B and C).
Increased MOG-specific proliferative response in
Hsp70.1-deficient mice
To determine the role of inducible Hsp70 in the immune
response, we investigated the proliferative capacity of Hsp70.1 KO
splenocytes. Spleens were removed at day 12 p.i. (inflammatory
phase) and at day 29 p.i. (chronic phase). Hsp70 deficiency
strongly enhanced the in vitro MOG-specific splenocyte prolifer-
ation compared with the WT cells in both the inflammatory
(14.3161.60 vs. 8.6061.39 p = 0.029) and chronic (12.8761.61
vs. 9.6760.68 p = 0.036) phases of the disease (Fig. 2A). Similarly,
WT mice administered with Hsp70.1-specific siRNA exhibited an
increased but not significant (p = 0.310) MOG-specific prolifera-
tive response in the chronic phase compared with the mice
administered with non-targeting siRNAs, although these differ-
ences were not significant (Fig. 2A).
Hsp70.1 deficiency did not alter the cytokine profile
To study whether the differential proliferative T cell response
between the Hsp70.1-deficient and control mice was associated
with a specific Th profile, cytokine release was analysed during the
inflammatory (day 12 p.i.) and chronic (day 29 p.i.) phases of the
disease. At day 12 p.i., we did not find any difference in the
examined cytokines potentially involved in the increase of the
MOG-specific cell proliferative response in Hsp70.1 KO mice. At
day 29 p.i., only a reduced production of IL-2 was detected in the
Hsp70.1 KO splenocytes, probably related with its consumption
due to the increased proliferative cell response observed in
Hsp70.1 KO mice. No differences were found between mice
treated with either Hsp70.1 or non-targeting siRNA (Fig. 2B).
Similar neuropathological alterations in Hsp70.1-deficient
and control mice
A histopathological study of Hsp70.1 KO and WT mice during
the inflammatory phase of EAE (day 12 p.i.) revealed the presence
of inflammatory infiltrates (consisting of neutrophiles, lymphocytes
and a few macrophages) in the white matter of the spinal cord and
subarachnoidal space of the brain, with discrete demyelination of
the brain stem. In the spinal cord, the inflammatory infiltration
(mainly consisting of macrophages and lymphocytes) was higher
and the demyelination was more extensive during the chronic
phase of the disease (day 29 p.i.) than during the inflammatory
phase of EAE. However, no differences were observed with
regards to inflammation or demyelination between the Hsp70.1
KO and WT mice at any phase of the disease (Fig. 3). As
expected, the Hsp70.1 KO mice that did not develop EAE did not
demonstrate inflammatory infiltration or demyelination in the
CNS (data not shown). Otherwise, the EAE mice with matched
clinical scores administered with either Hsp70.1 or non-targeting
siRNAs did not exhibit any differences in either inflammatory
infiltration or demyelination (Fig. 3).
Immunohistochemical studies using oxidative stress markers
revealed that the Hsp70.1 KO mice showed a significantly higher
expression of HOx (HOx: 66.3463.30 vs. 38.5063.54, p = 0.015)
at day 12 p.i., although the levels of MDA, NITT and iNOS
remained similar in both groups. In contrast, no differences were
observed in the numbers of infiltrating cells (CD45+ and CD3+
cells), macrophages/microglia (LEA+ cells) and astrocytes (GFAP+
cells) or in the axonal damage (SMI32+ cells) and remyelination
(NG2+ cells) in the spinal cord of the Hsp70.1 KO and WT mice
(Fig. 4).
In vitro model of CNS inflammation
A mixed culture of CNS cells consisting of 40.5% of neurons,
25.3% of oligodendroglial cells [20.9% O4+ cells (OPCs) and
4.4% MBP+ cells (mature oligodendrocytes)] and 34.2% astrocytes
was obtained from the Hsp70.1 KO or WT mice, as previously
described in the Material and Methods section. No intrinsic
microglia (isolectin B4+ cells) was detected in the CNS cell cultures
Figure 2. Increased MOG-proliferative response in the splenocytes of Hsp70.1-deficient mice. A. MOG-induced proliferative response of
Hsp70.1-deficient and control splenocytes. The data were expressed as the mean of the stimulatory indices (SI). The error bars correspond to the SEM.
Splenocytes from WT (.) and Hsp70.1 KO (N) mice were obtained during the inflammatory phase [day 12 p.i., (left graph), n = 4 in each group] and
chronic phase of EAE [day 29 p.i. (middle graph), WT: n = 3 and KO: n = 5]. Hsp70.1 KO splenocytes showed increased MOG-specific proliferation at day
12 p.i. (p = 0.029) and at day 29 p.i. (p = 0.036) compared with the WT splenocytes. The MOG-specific proliferation of splenocytes of non-targeting
(¤) or Hsp70.1 (#) siRNA-treated mice (right graph) was assessed at day 29 p.i. (n = 5 in each group). B. Determination of the cytokine Th1/Th2/Th17
profile secretion following MOG-specific stimulation of splenocytes from Hsp70.1-deficient (black columns) and WT (grey columns). The increased cell
proliferation of Hsp70.1-deficient splenocytes following antigen-specific stimulation was not related to an increase in cytokine production. A reduced
IL2 level was only detected at day 29 p.i. in the Hsp70.1 KO splenocytes, probably due to the increased proliferative splenocyte response observed in
these mice. The error bars represent the SEM.
doi:10.1371/journal.pone.0105737.g002
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Figure 3. Histopathological study of the spinal cords of Hsp70.1 KO, WT and siRNA-treated mice. HE staining (A, D, G, J, M, P) shows
inflammatory infiltration (arrow heads), and KB staining (B, E, H, K, N, Q) demonstrates demyelination (arrows) in the white matter of the spinal cord.
Detail of inflammatory infiltration and demyelination are shown. Similar levels of inflammation (A, D) and demyelination (B, E) were observed in the
WT and Hsp70.1 KO mice at day 12 p.i, when neutrophils and lymphocytes were detected and scanty demyelination was observed (C, F). At day 29 p.i,
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(data not shown). To determine the optimal conditions to induce
apoptosis after 24 or 48 h of incubation, the culture medium was
replaced with fresh medium containing a different number of
microglial cells in combination with increased concentrations of
LPS and IFN-c. We established that after 24 h of incubation
16,000 microglial cells activated with 100 ng/ml LPS and 100 ng/
ml IFN-c induced apoptosis (Casp3+ cells) while those cultures
containing non-activated microglia hardly showed apoptotic cells
(Table 1 and Fig. 5).
Effect of the inflammatory stimulus in the CNS cell
cultures
As shown in Table 1, after an inflammatory stimulus we
observed a significant increase in the percentage of apoptotic cells
(Casp3+ cells) in both Hsp70.1 KO (p,0.001) and WT (p = 0.025)
CNS cell cultures. Among the different apoptotic cells, OPCs
(O4+Casp3+ cells) were the most affected in both groups. We were
not able to detect apoptotic mature oligodendrocytes (MBP+
Casp3+ cells) or apoptotic neurons (NeuN+Casp3+ cells) (data not
shown). Altogether these data suggest that OPCs are susceptible to
the induction of apoptosis upon an inflammatory stimulus.
To investigate the cytoprotective functions of Hsp70.1, we
studied the vulnerability of OPCs to the inflammatory stress in
Hsp70.1 KO compared with WT CNS cell cultures. When the
apoptotic induction was analysed, we did not observe a statistically
significant difference in the fold change of apoptotic OPCs (O4+
Casp3+) in Hsp70.1 KO respect to WT CNS cell cultures
(Table 1, Fig. 6). These data suggest that the absence of Hsp70 did
not influence the susceptibility of OPCs (O4+ cells) to inflamma-
tion-induced apoptosis.
WT and Hsp70.1 KO mice had similar degree of inflammation (G, J), mainly composed by lymphocytes and macrophages (I, L), with evident
demyelination (H, K, I, L). No differences were observed in inflammation (M, P, O, R) and demyelination (N, Q, O, R) in the mice treated with non-
targeting siRNA compared with those treated with Hsp70.1 siRNA. Representative mice with a clinical score of 4 are shown in the figure. Graphs
represent qualitative inflammatory (S) and demyelination (T) scores, assessed by HE and KB respectively, for WT and Hsp70.1 KO mice at day 12 p.i.
and 29 p.i., and also for mice treated with either non-targeting or Hsp70.1 siRNA at day 29 p.i.
doi:10.1371/journal.pone.0105737.g003
Figure 4. Immunoshitochemical staining for GFAP, SMI32, NG2 and HOx of the spinal cord of Hsp70.1 KO and WT mice.
Immunohistochemical staining for GFAP (astrocytes), SMI32 (axonal damage) and NG2 (oligodendrocyte progenitor cells) was performed in Hsp70.1
KO and WT mice at days 12 p.i. or 29 p.i. Hsp70.1 KO mice showed higher expression of oxidative stress marker HOx than WT mice at day 12 p.i.
Arrows indicate positive stained cells.
doi:10.1371/journal.pone.0105737.g004
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Figure 5. Apoptotic induction in CNS cell cultures. Apoptotic immunocytochemical detection in oligodendrocyte precursor cells (OPCs, O4+
cells) and mature oligodendrocytes (MBP+ cells) in mixed CNS cell cultures of WT and Hsp70.1 KO mice under non-stimulated (left column) and LPS
plus IFN-c-stimulated (right column) culture conditions. A. Detection of apoptotic OPCs cells (O4+Casp3+ cells). The rows indicate the O4+Casp3+
cells. B. Detection of apoptotic mature oligodendrocytes (MBP+Casp3+ cells).
doi:10.1371/journal.pone.0105737.g005
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Discussion
Several recent studies have described the important role of
Hsp70 not only as an essential chaperone but also as an anti-
apoptotic mediator and promoter of both innate and adaptive
immune responses [11–13,15,16,18,35–37]. To study the role of
Hsp70 in the pathogenesis of MS, we used a MOG-induced EAE
animal model. We observed that Hsp70.1 KO mice were
significantly more resistant to EAE development compared with
their WT littermates. Nevertheless, the Hsp70.1 KO mice that
developed clinical symptoms of EAE showed the same clinical
course and histopathological characteristics as the WT mice. Thus,
Hsp70.1 appears to be relevant, but not crucial, for the EAE
outcome. These results are partially consistent with previous
studies performed by Mycko and colleagues, in which all animals
developed clinical signs of the disease but the Hsp70.1 KO mice
developed a milder form of EAE. Furthermore, these authors also
demonstrated that the passive transference of Hsp70.1-deficient
lymphocytes with either MOG antigen- or polyclonal restimula-
tion did not induce EAE in C57BL/6 WT mice [38].
Knock-out mouse technology is an important approach used to
investigate the function of genes that are not essential for
embryogenesis and development in the animal. However, under
some circumstances, KO mice develop compensatory mechanisms
that overcome the genetic deficiency [39]. One of the most
common compensatory mechanisms consists of the up-regulation
of genes with the same or similar functions. The inducible form of
Hsp70 is encoded by the Hsp70.1 and Hsp70.3 genes, although
the Hsp70.1 gene deletion is well known to be sufficient to
abrogate inducible Hsp70 activity in mice [40]. As Hsp70 is a
relevant protein for homeostatic functions following stressful
situations, it would be plausible that Hsp70.1 KO mice would
develop some compensatory mechanisms. For this reason, we
performed an experiment using siRNA technology to down-
regulate the Hsp70.1 protein expression after EAE induction. To
achieve this outcome, we first immunised WT mice with the
MOG35–55 peptide. When the first EAE clinical symptoms were
detected, the animals were randomised into two groups and then
injected with either Hsp70.1 or non-targeting siRNA. The mice
also received a second dose of siRNA on day 14 p.i. Compared
with the mice administered with non-targeting siRNAs, mice in
which Hsp70.1 expression was down-regulated showed an
improved EAE clinical course, and one mouse even remained
disease-free. In agreement with these data, we previously
demonstrated a baseline-increased expression of the HSPA1A
gene in PBMCs from MS patients compared with HDs. In
addition, we observed an increase in the protein expression of
inducible Hsp70 in T lymphocytes (CD4+ and CD8+) and
monocytes from MS patients under basal conditions that may
reflect the immunological activation occurring in MS patients
[29]. Taken together, these data confirmed and further supported
the Hsp70.1 KO mice results and indicate a relevant role of
Hsp70.1 in the EAE outcome.
Previous studies have shown that Hsp70 released into the milieu
can act as a danger signal or proinflammatory mediator, thereby
inducing innate immune responses via the TLR2/4 and CD14
Table 1. Characterisation of the non-stimulated CNS cell cultures and following an inflammatory stimulus.
Non-stimulated LPS+IFN-c stimulation Fold change
% O4+ cells WT 20.9460.09 15.8760.22 0.7660.01
Hsp70.1 KO 15.0965.43 10.0963.23 0.6760.03
% MBP+ cells WT 4.3760.75 2.8560.07 0.6760.13
Hsp70.1 KO 2.9360.13 1.1560.97 0.3960.32
% Casp3+ cells WT 1.8060.63 4.0161.66 2.5160.86
Hsp70.1 KO 2.3160.58 3.5760.63 1.6060.33
% O4+Casp3+ cells WT 0.5160.43 2.196 0.28 6.4564.96
Hsp70.1 KO 0.9760.36 1.646 0.58 1.7060.13
The percentage of O4+, MBP+ and Casp3+ cells from the total number of cells of non-stimulated or LPS plus IFN-c-stimulated cultures from wild-type (WT) and Hsp70.1
knock-out (KO) mice after 24 h. Fold change induced by inflammatory stimulus of each population was calculated referred to matched non-stimulated cultures. The
results were expressed as the mean6SD.
doi:10.1371/journal.pone.0105737.t001
Figure 6. Oligodendrocyte precursor cell susceptibility to
apoptotic induction following inflammatory stress. Analysis of
Casp3 expression in O4+ cells following an inflammatory stress. The fold
change of apoptotic (Casp3+) and viable (Casp3-) O4+ cells was similar
in the WT and Hp70.1 KO CNS cell cultures after 24 h of stimulation with
LPS plus IFN-c. The error bars correspond to the SEM.
doi:10.1371/journal.pone.0105737.g006
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receptors [13,35,37]. Furthermore, extracellular Hsp70 can act as
an adjuvant that promotes adaptive immune responses against
specific antigens. In this context, complexes of Hsp70 and either
MOG or MBP were found in MS lesions, and complexes of Hsp70
and either MOG or PLP were present in the CNS of mice with
EAE [19,27,28]. In contrast to our expectations, splenocytes
lacking Hsp70.1 were able to induce an antigen-specific prolifer-
ative response, and Hsp70.1 KO mice with EAE also exhibited a
higher MOG-specific proliferative response compared with WT
mice in the inflammatory and chronic phases of the disease.
Nevertheless, the high proliferative response observed in the
incident Hsp70.1 KO mice was not related to an increased
cytokine production in either the inflammatory or chronic phase of
the disease. We only observed a reduction of the IL-2 levels in the
Hsp70.1 KO splenocytes compared with the WT cells, probably
related with its consumption due to the increased proliferative cell
response observed in Hsp70.1 KO mice. We confirmed these
results using siRNA technology to abrogate Hsp70.1 protein
expression after EAE induction. Otherwise, the differences in the
proliferative response did not involve differences in the extension
of the inflammatory infiltrate observed in the spinal cords of
incident Hsp70.1 KO and WT mice in both the inflammatory and
chronic phases of EAE, and the same was observed when siRNAs
were used. However, it is remarkable to note that although we
observed a higher clinical improvement in the Hsp70.1 siRNA
treated mice than in Hsp70.1 KO mice, the differences in
splenocyte proliferation were milder using siRNAs. siRNA
technology allows to avoid compensatory mechanisms that
Hsp70.1 KO mice could have developed. Thus, the clinical effect
of Hsp70.1 deficiency would be more potent in mice treated with
Hsp70.1 siRNA than in Hsp70.1 KO mice. However the effect of
siRNA is transitory and we performed splenocyte proliferation
studies in siRNA-treated mice only at the end of the experiment
(day 29 p.i.), 15 days after the last siRNA administration. The fact
that at this time we were not able to detect down-regulation of
Hsp70.1 protein expression could explain the differences in
splenocyte proliferation between the two approaches that we used
to inhibit the expression of Hsp70.1. Taken together, these data
might indicate that only animals that developed an enhanced
MOG-response achieved a sufficient level of cytokine production
to proper establish an inflammatory environment to develop EAE.
Mycko and colleagues reported that Hsp70.1-deficient CD4+ T
cells were more susceptible to apoptosis following anti-CD3
stimulation [38], thereby supporting our hypothesis that Hsp70.1
KO mice required a higher number of antigen-specific T cells
compared with the WT mice to induce an effective response
against myelin antigens.
Classically, HSPs, including Hsp70, have been defined as
proteins involved in proper protein folding with cytoprotective
functions under stressful conditions [1–4,6–8]. However, Hsp70
over-expression in neuronal cell cultures and mouse models of
some neurodegenerative diseases have demonstrated a beneficial
reduction in abnormal protein aggregation, such as amyloid
peptides [41,42], tau protein [43], huntingtin [44] and a-synuclein
fibril formation [45]. To study the function of inducible Hsp70 as
a cytoprotective molecule in the CNS under inflammatory
conditions occurring in EAE and MS, we established an in vitro
model consisting of a mixed CNS cell culture in which an
inflammatory stimulus was induced. We observed that Hsp70.1
deficient CNS cell cultures did not present a higher vulnerability to
the induction of apoptosis in OPCs (O4+ cells) under inflamma-
tory conditions compared with WT CNS cell cultures. Accord-
ingly, when histopathological studies were performed in Hsp70.1-
deficient mice that developed EAE, in both Hsp70.1 KO mice and
Hsp70.1 siRNA-treated mice, neither the number of NG2+ cells
(OPCs) nor the extent of demyelination were affected. In addition,
the amount of axonal damage or astrogliosis were comparable to
those observed in the WT or non-targeted siRNA-treated mice.
Conclusions
Our results indicated that although Hsp70.1 could play a role in
both the immune response and cytoprotection of CNS cells, in the
MOG-induced EAE model, Hsp70.1 seems to play a more
relevant role in promoting an effective T cell response against the
auto-antigen compared with its role in protecting CNS cells from
inflammatory injury. Consequently, specific therapies down-
regulating the expression of Hsp70 may be a promising approach
to reduce or control the early autoimmune response in MS
patients.
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